Article

Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2-amplified gastric cancer

2024-11-06

Abstract excerpt

Fibroblast growth factor receptor 2 (FGFR2) is an important member of receptor tyrosine kinase (RTK) family. FGFR2 amplification occurs at a high frequency in gastric cancer (GC) and has been proven to be closely associated with poor prognosis and insensitivity to chemotherapy or immunotherapy. Current FGFR2-targeted therapies have limited efficacy. Hence, how to enhance efficacy and reverse resistance are urgent...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a2f7109e-d4c0-52f6-a7d3-58cfe6b7f8a5
DOI: 10.1101/2024.11.04.621870

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2-amplified gastric cancerDOI 10.1101/2024.11.04.621870Read

Strategies to overcome drug resistance using SHP2 inhibitorsSemantic proximity Read

Acquired FGFR2 mutation leads resistance to pemigatinib in a patient with FGFR2-driven Borrmann type IV gastric cancer.Semantic proximity Read

FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre studySemantic proximity Read

FGFR-TKI resistance in cancer: current status and perspectives.Semantic proximity Read

To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting InhibitorsSemantic proximity Read

Targeting SHP2 phosphatase in hematological malignancies.Semantic proximity Read

FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival.Semantic proximity Read

FGFR families: biological functions and therapeutic interventions in tumorsSemantic proximity Read

Fibroblast Growth Factor 2 (FGF2) Activates Vascular Endothelial Growth Factor (VEGF) Signaling in Gastrointestinal Stromal Tumors (GIST): An Autocrine Mechanism Contributing to Imatinib Mesylate (IM) ResistanceSemantic proximity Read

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.Semantic proximity Read

FGFR2 gene amplification and clinicopathological features in gastric cancerSemantic proximity Read

SHP2 inhibition mitigates adaptive resistance to MEK inhibitors in KRAS-mutant gastric cancer through the suppression of KSR1 activity.Semantic proximity Read